Esta lista es un análisis basado en eventos recientes del mercado. No es una recomendación de inversión.
Acerca de
PILA PHARMA AB (publ) operates as a clinical stage pharmaceutical company in Sweden. It is developing XEN-D0501, a TRPV1 antagonist that has completed two phase 2b clinical trials for type 2 diabetes. The company was incorporated in 2014 and is based in Malmö, Sweden.